Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ResilMS

Financiado

Deciphering SNPs involved in oligodendroglia functional resilience in multiple s...

Multiple sclerosis (MS) is a prevalent demyelinating disease that primarily affects young adults. Current therapy for MS mainly focuses on immune suppression and alleviating inflammation. However, efforts to promote remyelination... ver más

31/05/2026

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-06

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023

I+D

Cerrada hace 1 año

0% 100%

1 Participantes

206.89K€ | Lider

Proyectos interesantes

EPIScOPE Reversing the epigenetic state of oligodendrocyte precursors... 2M€ Cerrado

SingleMS Unveiling the functional outcome of single nucleotide polymo... 3M€ Cerrado

ImmunoMet Immunometabolic regulation of microglia function in stroke r... 165K€ Cerrado

SAF2012-40023 MIELINA: DESDE LA OLIGODENDROGENESIS A LAS ENFERMEDADES DESM... 187K€ Cerrado

BES-2013-062630 MIELINA: DESDE LA OLIGODENDROGENESIS A LAS ENFERMEDADES DESM... 84K€ Cerrado

PID2021-129053OB-I00 PLASTICIDAD DE MICROGLÍA EN DEMENCIA 169K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 26 meses Fecha Inicio: 2024-03-06
Fecha Fin: 2026-05-31

Líder del proyecto

KAROLINSKA INSTITUTET

TRL 4-5

Presupuesto del proyecto 207K€

Descripción del proyecto Multiple sclerosis (MS) is a prevalent demyelinating disease that primarily affects young adults. Current therapy for MS mainly focuses on immune suppression and alleviating inflammation. However, efforts to promote remyelination face challenges in clinical translation. Animal models of acute demyelination have demonstrated promising remyelination, primarily facilitated by newly generated oligodendrocytes. Nevertheless, the scenario in human MS differs, as the disease typically manifests in adulthood and the progression of lesions occurs over several decades. In the proposed project ResilMS, by using barcode based lineage tracing combined with ultra-depth single-cell and spatial transcriptomics, I will identify the molecular profiles of existing and newly generated oligodendrocytes at different stages of a mouse model induced with experimental autoimmune encephalomyelitis (EAE). The aim is to comprehend how an oligodendroglial cell pool diversifies its subpopulations during prolonged disease challenge, and what are the unique molecular properties for resilient cells to maintain their ability to endure an adverse inflammatory environment and remyelinate. Further, I will perform a screen of single nucleotide polymorphisms (SNPs) associated with risk and severity of MS that might affect genes related to the resilience of oligodendrocytes. To experimentally explore the effect of relevant SNPs, human oligodendrocyte cells (hOLGs) derived from pluripotent cells will be perturbed with CRISPR-based genetic modification and observed for cell profile and functional changes. The identified SNPs and resilience molecular pathways may play a critical role in disease progression for MS patients. By delving into the mechanisms of resilience of (re)myelinating cells in a long disease course, this project will provide valuable insights into MS-related genetic risk and protective factors, and potentially advance diagnostic and therapeutic approaches in MS research.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores